COST EFFECTIVENESS OF ONASEMNOGENE ABEPARVOVEC IN INFANTS WITH PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY IN ITALY

被引：0
|
作者：
Valentini, I [1 ,2 ]
Ghetti, G. [3 ]
Pane, M. [4 ]
Cicchetti, A. [1 ,2 ]
Rumi, F. [5 ]
Di Brino, E. [1 ,2 ]
Basile, M. [5 ]
Pistillo, G. [6 ]
Bischof, M. [7 ]
机构：
[1] Cattolica Sacro Cuore Univ UCSC, Fac Econ, Rome, Italy
[2] Cattolica Sacro Cuore Univ, Grad Sch Hlth Econ & Management ALTEMS, Rome, Italy
[3] AdRes HEOR, Turin, To, Italy
[4] Fdn Policlin Univ Agostino Gemelli, Rome, Italy
[5] Univ Cattolica Sacro Cuore, Grad Sch Hlth Econ & Management ALTEMS, Rome, Italy
[6] Novartis Gene Therapies, Legnano, MI, Italy
[7] Novartis Gene Therapies GmbH, Rotkreuz, Switzerland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD129
引用
收藏
页码：S528 / S529
页数：2
相关论文
共 50 条
  • [41] Acute Benign Myositis Following Onasemnogene Abeparvovec Therapy in Type 1 Spinal Muscular Atrophy
    Dosi, Claudia
    Tozzo, Alessandra
    Masson, Riccardo
    PEDIATRIC NEUROLOGY, 2022, 131 : 23 - 24
  • [42] Outcomes of Children Treated With Nusinersen/Onasemnogene Abeparvovec for Pediatric Spinal Muscular Atrophy Type 1
    Chacko, A.
    Sly, P. D.
    Gauld, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [43] Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy
    Rene, Charlotte A.
    Parks, Robin J.
    PHARMACEUTICS, 2023, 15 (06)
  • [44] Risdiplam experience following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series
    Kuntz, N.
    Svoboda, M.
    Leon-Astudillo, C.
    Byrne, B.
    Krueger, J.
    Kwon, J.
    Sieburg, C.
    Castro, D.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S162 - S162
  • [45] Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study
    Stettner, Georg M.
    Hasselmann, Oswald
    Tscherter, Anne
    Galiart, Elea
    Jacquier, David
    Klein, Andrea
    BMC NEUROLOGY, 2023, 23 (01)
  • [46] Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec
    Matesanz, Susan E.
    Curry, Candace
    Gross, Brianna
    Rubin, Adam I.
    Linn, Rebecca
    Yum, Sabrina W.
    Kichula, Elizabeth A.
    JOURNAL OF CHILD NEUROLOGY, 2020, 35 (11) : 717 - 723
  • [47] Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
    Mirea, Andrada
    Shelby, Elena-Silvia
    Axente, Mihaela
    Badina, Mihaela
    Padure, Liliana
    Leanca, Madalina
    Dima, Vlad
    Sporea, Corina
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [48] Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec - A Single Centre Experience
    Friese, Johannes
    Geitmann, Stephanie
    Holzwarth, Dorothea
    Mueller, Nicole
    Sassen, Robert
    Baur, Ute
    Adler, Kristin
    Kirschner, Janbernd
    JOURNAL OF NEUROMUSCULAR DISEASES, 2021, 8 (02) : 209 - 216
  • [49] Onasemnogene abeparvovec gene-replacement therapy for spinal muscular atrophy: From bench to bedside
    Kaufmann, P.
    Kausar, I.
    Foust, K. D.
    Kaspar, A.
    Kaspar, B. K.
    Mendell, J. R.
    HUMAN GENE THERAPY, 2019, 30 (08) : A9 - A9
  • [50] ONASEMNOGENE ABEPARVOVEC GENE-REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY: FROM BENCH TO BEDSIDE
    Kaufmann, P.
    Kausar, I.
    Foust, K. D.
    Kaspar, A.
    Kaspar, B. K.
    Mendell, J. R.
    THORAX, 2019, 74 : A109 - A109
12345